Physician profile
David G Kirschen
NPI 1821048141
$9,012.59
in general payments reported to CMS, 2019-2025
13 companies · $3,117 in 2025
The $3,117 reported for 2025 was more than what 97% of Pediatrics (Optometrist) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $68.45 · 2021: $177 · 2022: $579 · 2023: $2,221 · 2024: $2,398 · 2025: $3,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,125 · Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,125.00 |
| Food and Beverage | $610.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $7,512.95 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $359.39 | 2019-2025 | Cequa |
| Glaukos Corporation | $291.08 | 2022-2023 | |
| Sight Sciences, INC. | $246.72 | 2019-2025 | Tearcare System |
| Allergan, INC. | $154.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $144.72 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2019 | |
| Rxsight INC | $57.85 | 2022 | |
| Visionix USA, INC | $41.67 | 2022 | |
| Bausch & Lomb Americas INC. | $23.27 | 2025 | Xiidra |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Coopervision INC. | $19.13 | 2020 | |
| Biotissue Holdings INC. | $16.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kirschen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.